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placebo group (difference in cost 4247,36 USD). Incremental
CER was 20 360,90 USD for one patient with viral load <50
copies/ml (16 462,65–41 640,81 USD in sensitivity analysis).
Cost of one patient with achieved viral load <50 copies/ml was
lower for ETR group. CONCLUSIONS: According to the model
ETR seems to be much more effective than placebo with afford-
able CER incremental ratio. Evaluation of ETR treatment cost-
effectiveness in common practice in Russian health care is
needed.
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OBJECTIVES: It is estimated that annually 300,000 cases of
rotavirus-induced gastroenteritis (RVGE) occur in children aged
up to 5 years in France. RIX4414 (Rotarix™ GlaxoSmith-
Kline), a two-dose oral vaccine against rotavirus infection, has
been shown to be highly effective against severe RVGE. A
recent study (Melliez et al, Vaccine 2008) concluded that
rotavirus vaccination was not cost-effective according to French
Public Health context. We evaluated the cost-effectiveness of
general vaccination against rotavirus using Rotarix™ in France
using an updated model. We investigated the differences in
modelling approaches and resultant cost-effectiveness conclu-
sions. METHODS: A Markov model simulated RVGE events
and the associated outcomes and costs in a birth cohort of
children in France (n = 750,000), adjusting for age distribution
and seasonality of infection. Costs and outcomes were esti-
mated from a limited societal perspective (without indirect
costs). The primary outcome measure was the incremental cost
per quality-adjusted life year (QALY). RESULTS: Vaccination
with Rotarix™ incurred an incremental cost of €44,583/QALY
at a public price of €57 per vaccine dose. Univariate sensitivity
analyses showed that the results were largely inﬂuenced by the
discount rate for beneﬁts, nosocomial rotavirus infection
burden, hospital costs, and vaccine efﬁcacy and cost. The
acceptability curve indicated that 60% of the results were
under the threshold of €50,000/QALY. Comparing these results
with those of Melliez et al, the apparent discrepancy can be
largely explained by differences in model structure and data
input values including: different at-risk period and time
horizon; different vaccine efﬁcacy; different unit cost data; dif-
ferent disease duration and disutility values. CONCLUSIONS:
These results demonstrate that a generalized vaccination strat-
egy with Rotarix™ would be cost-effective in France from a
societal perspective without including indirect costs; however
there is a need for agreed standards to improve comparability
of results from different studies.
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OBJECTIVES: The aim of this study is to evaluate the long-
term economic cost-effectiveness and clinical impact of univer-
sal infant vaccination of 7-valent pneumococcal conjugate
vaccine (PCV7) in Taiwan by using a dynamic SIR model.
METHODS: Recently, there are lots of interests surrounding
the cost-effectiveness of PCV7 against pneumococcal diseases.
Particularly, the quantiﬁcation of the herd-immunity effects
caused by this vaccine has been widely discussed. A cohort
model in our previous study indicated that the universal PCV7
vaccination in Taiwan is a cost-effective intervention with
an incremental cost per life year gained of NT344,928
(US$11,227), preventing thousands of IPD cases over a 10-year
horizon. However, this model cannot dynamically capture age-
dependent force of infection associated with the effects of dif-
ferent contact patterns on pre- and post-vaccination. Hence, the
herd-immunity externalities cannot be correctly estimated,
which would bias our ﬁndings. To reassess the cost-effectiveness
of this vaccine, we incorporated a dynamic realistic age-
structured Susceptible-Infected-Recovered (SIR) model that can
account for both the direct and indirect (i.e. herd-immunity
effects) beneﬁts of vaccination. All pre-vaccination parameters
such as age-speciﬁc disease incidence, mortality, seroprevalence
data, and cost associated with the treatment of pneumococcal
diseases were obtained from the National Health Insurance
(NHI) Database and published literature where available. A
societal perspective and a health care payer’s perspective were
adopted. Various vaccine strategies including hypothetical sce-
narios were investigated. One-way and multi-way sensitivity
analyses were also performed to evaluate model robustness.
RESULTS: Our model suggests that universal PCV7 vaccina-
tion has a considerable impact on the reductions of the mor-
bidity and incidence related to pneumococcal diseases where
the herd-immunity effects are more precisely quantiﬁed using
dynamic SIR model. CONCLUSIONS: A universal infant vac-
cination with PCV7 is a cost-effective intervention from a
dynamic perspective and its continuous vaccination in Taiwan
is greatly encouraged.
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OBJECTIVES: The Phase III TITAN trial (TMC114-C214)
evaluated darunavir/ritonavir (DRV/r) 600/100 mg bid versus
lopinavir/ritonavir (LPV/r) 400/100 mg bid in treatment-ex-
perienced, LPV/r-naïve, HIV-infected adults. We determined the
cost-effectiveness of DRV/r versus LPV/r from the perspective of
British, Swedish, Italian and Belgian payers in the TITAN trial
subgroup with at least one IAS-USA primary protease inhibitor
(PI) mutation at baseline. These patients had less advanced HIV
disease and a broader degree of prior PI use/failure (0 = 2) than
those in the DRV Phase IIb POWER trials (= 2). METHODS: An
existing Markov model containing 6 CD4+ T-cell count (CD4
count)-deﬁned health states and a “death” state was adapted to
the abovementioned countries. Baseline demographics and CD4
count distribution, antiretroviral drug usage, virologic and
immunologic response rates and matching transition probabili-
ties were based on TITAN trial data collected in the modelled
subgroup during the ﬁrst 48 weeks of therapy and from pub-
lished literature. Patients were assumed to switch to a follow-up
combination therapy after failure. For each model state, utility
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